Feng Chang, Bo Bing, Mao Xiaoxia, Shi Hai, Zhu Xiaoli, Li Genxi
Center for Molecular Recognition and Biosensing, School of Life Sciences, Shanghai University, Shanghai 200444, P. R. China.
Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, P. R. China.
Theranostics. 2017 Jan 1;7(1):31-39. doi: 10.7150/thno.16671. eCollection 2017.
Both the 3D solution and the 2D interface play important roles in bioanalysis. For the former, reactions can be carried out adequately; while for the latter, interfering substance can be eliminated simply through wash. It is a challenge to integrate the advantages of solution-based assays and the interface-based assays. Here, we report an immuno-NRCA (netlike rolling circle amplification) strategy, which integrates immunoassay with NRCA for the ultrasensitive detection of tumor biomarker, by taking the assay of a tumour marker as an example. In this strategy, immunoreactions occur on interface, while the target-induced signal amplification can be completed totally in solution. As a result, this system has the merits of both solution- and interface-based assays. The whole procedure of this novel strategy is similar to the conventional ELISA, inheriting the usability. But in comparison with ELISA, the performance is greatly improved. The detection limit can be lowered to 5.5 fg/L, making it possible to detect the target tumour marker in one drop of blood. Also, in comparison with established immuno-PCR method, which integrates immunoassay with the commonly used nucleic acid amplification approach, this system has no requirement for thermal cycler owing to the isothermal amplification, and it has the ability to retain the immunoreactivities. So, the new immunoassay method proposed in this study may have more feasible applications in the future.
3D 溶液体系和 2D 界面在生物分析中都发挥着重要作用。对于前者,反应能够充分进行;而对于后者,干扰物质可以通过洗涤简单地消除。整合基于溶液的检测方法和基于界面的检测方法的优势是一项挑战。在此,我们报道了一种免疫 NRCA(网状滚环扩增)策略,以肿瘤标志物检测为例,该策略将免疫分析与 NRCA 整合用于肿瘤生物标志物的超灵敏检测。在该策略中,免疫反应在界面上发生,而靶标诱导的信号放大可在溶液中完全完成。因此,该系统兼具基于溶液的检测方法和基于界面的检测方法的优点。这种新策略的整个过程与传统酶联免疫吸附测定(ELISA)相似,继承了其易用性。但与 ELISA 相比,性能有了很大提高。检测限可低至 5.5 fg/L,使得在一滴血中检测靶标肿瘤标志物成为可能。此外,与将免疫分析与常用核酸扩增方法整合的成熟免疫 PCR 方法相比,由于等温扩增,该系统无需热循环仪,并且具有保留免疫反应性的能力。所以,本研究中提出的新免疫分析方法在未来可能有更可行的应用。